Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
licogliflozin + tropifexor
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Licogliflozin + tropifexor is an investigational oral fixed-dose combination therapy developed for the treatment of nonalcoholic steatohepatitis (NASH) and liver fibrosis. Licogliflozin is a dual sodium-glucose cotransporter 1 and 2 (SGLT1/2) inhibitor, which reduces glucose reabsorption in the kidney and intestine, leading to improved glycemic control and potential metabolic benefits. Tropifexor is a potent farnesoid X receptor (FXR) agonist that modulates bile acid metabolism, inflammation, and fibrosis pathways in the liver. The combination aims to address both metabolic dysfunction and fibrotic progression in NASH by targeting complementary mechanisms. Clinical studies have evaluated its efficacy, safety, tolerability, pharmacokinetics, and drug-drug interactions in adults with NASH with stage 2 or 3 fibrosis[4][5][6][9].
- Other names
- tropifexor + licogliflozin
02
Targets
SGLT2 (Sodium-glucose cotransporter protein subunit 2)SLC5A1 (Sodium Glucose Cotransporter 1)FXR (Farnesoid x-activated receptor)
Beyond the preview
Go deeper on licogliflozin + tropifexor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on licogliflozin + tropifexor.